<SEC-DOCUMENT>0001193125-24-287086.txt : 20241231
<SEC-HEADER>0001193125-24-287086.hdr.sgml : 20241231
<ACCEPTANCE-DATETIME>20241231084910
ACCESSION NUMBER:		0001193125-24-287086
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241231
DATE AS OF CHANGE:		20241231

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279773
		FILM NUMBER:		241591246

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d904974d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773</FONT></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
December&nbsp;2, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>8,850,000 American Depositary Shares representing </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>885,000,000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary
Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g904974g1227014702288.jpg" ALT="LOGO" STYLE="width:2.25139in;height:0.645833in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December&nbsp;2, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773),</FONT> with the information contained in our
current report on <FONT STYLE="white-space:nowrap">Form&nbsp;6-K,</FONT> furnished to the Securities and Exchange Commission on December&nbsp;31, 2024 (the &#147;December&nbsp;31, 2024 <FONT STYLE="white-space:nowrap">Form&nbsp;6-K&#148;).</FONT>
Accordingly, we have attached the December&nbsp;31, 2024 <FONT STYLE="white-space:nowrap">Form&nbsp;6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This
prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On December&nbsp;30, 2024, the last reported
sale price of the ADSs on Nasdaq was $3.10 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is December&nbsp;31, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;31, 2024, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled &#147;Kazia
Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA&#148;. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr.&nbsp;John
Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company&#146;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT
STYLE="white-space:nowrap">333-281937).</FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated December&nbsp;31, 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 31 December 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">31&nbsp;December 2024 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kazia Therapeutics Provides Update
on Paxalisib Regulatory Pathway Following Type C Meeting with FDA </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, December&nbsp;31, 2024&#150;Kazia Therapeutics Limited (NASDAQ: KZIA),
an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2024, the Company reported topline results from the <FONT STYLE="white-space:nowrap">GBM-AGILE</FONT> study in which newly diagnosed unmethylated
(NDU) patients with glioblastoma treated with paxalisib showed a clinically meaningful improvement in a prespecified secondary analysis for overall survival (OS) compared to standard of care. Based on these results and the totality of data from all
completed paxalisib clinical studies, Kazia requested a meeting with the FDA to discuss potential clinical and regulatory paths forward. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following
discussions with the FDA and feedback from Kazia&#146;s recent Type C meeting, the FDA&#146;s current position is that data on OS would generally not be appropriate for accelerated approval, but could be considered to support a traditional/standard
approval. The Agency further commented that the secondary endpoint OS data from the <FONT STYLE="white-space:nowrap">GBM-AGILE</FONT> study are supportive and informative for designing and executing a pivotal registrational study in pursuit of a
standard approval. Importantly, the Company aligned with the FDA on key aspects of the design of a proposed registrational/pivotal phase 3 study, including patient population, primary endpoint, and the comparator arm to be used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We appreciate the extensive and thoughtful feedback from the FDA, which provides us with added clarity with respect to paxalisib&#146;s potential
registration pathway for the treatment of patients with NDU glioblastoma&#148; commented Dr.&nbsp;John Friend, Kazia&#146;s CEO &#147;We believe data from the <FONT STYLE="white-space:nowrap">GBM-AGILE</FONT> trial, including the prespecified
secondary endpoint, which demonstrated a <FONT STYLE="white-space:nowrap">3.8-month</FONT> OS improvement, provides evidence supporting a clinically meaningful efficacy signal that merits further testing paxalisib in this patient population in a
larger, pivotal study&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As we evaluate our next steps in NDU glioblastoma, paxalisib continues to be tested in a number of other key
indications, including pediatric brain cancer and brain metastases.&nbsp;We have received Orphan Drug and Rare Pediatric Disease Designations for both DIPG and AT/RT, which could make us eligible to receive pediatric review vouchers at the time of
product approval. We recently presented very exciting data at the San Antonio Breast Cancer meeting highlighting synergistic activity between a novel combination of paxalisib and immunotherapy, and we believe paxalisib shows potential to be
evaluated in breast cancers where iPI3K pathway mutations are known to drive tumor growth. The Kazia team, in conjunction with the Board of Directors, is continuing to evaluate several options, and we expect to provide an outline for our path
forward to maximize shareholder value by the end of January 2025.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Investor Contact: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alex Starr </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LifeSci Advisors LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-201-786-8795</FONT></FONT></FONT> <B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Astarr@lifesciadvisors.com</B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an
investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this
disease. A completed Phase 2/3 study in glioblastoma <FONT STYLE="white-space:nowrap">(GBM-Agile)</FONT> was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval.
Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for
glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in
combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in
June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and
has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit
www.kaziatherapeutics.com or follow us on X @KaziaTx. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials,
Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory
agencies, and the potential market opportunity for paxalisib. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and
uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to
regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC,
and in subsequent </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release on behalf of the Board of Directors by Dr John Friend, CEO. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g904974g1227014702288.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g904974g1227014702288.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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MIC&*Z!M0@2W2<OE'X7'4FA]1@2!9BQVN=H&.2?I3<I/<5X(NUY_XC^&_]O\
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+BDHH 6BDHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
